Pharma/Biotech Deals: Are Today’s Collaborations Tomorrow’s Acquisitions?
Executive Summary
Big pharma and biotech companies are increasingly looking at collaborations as a pathway to acquisition, Kirkpatrick & Lockhart attorney Eileen Smith Ewing said at the Biotechnology Industry Organization annual meeting in Washington, D.C. June 23
You may also be interested in...
J&J Adds New Dimension To Drug Discovery Efforts With 3DP Acquisition
Johnson & Johnson's purchase of 3-Dimensional Pharmaceuticals has more of a research focus than its other recent drug acquisitions
J&J Increases Alza Ante By $5 Bil. Over Abbott: Concerta Has J&J Upbeat
Johnson & Johnson is offering about 67% ($5 bil.) more than Abbott did in 1999 to bring Alza's $700 mil. annual sales product line and its extended-release product development skills into the J&J family.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011